Evidence map›Paper›PMID 29236688›Full record

ArticleNature2017

Evolution of a designed protein assembly encapsulating its own RNA genome.

Gabriel L Butterfield, Marc J Lajoie, Heather H Gustafson, Drew L Sellers, Una Nattermann, Daniel Ellis, Jacob B Bale, Sharon Ke, Garreck H Lenz, Angelica Yehdego and 4 more

Abstract read
In one paragraph

Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Chemical reviews · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Measuring the selective packaging of RNA molecules by viral coat proteins in cells.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Review
  15. Assembly and Functionality of 2D Protein Arrays.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  16. Article
  17. Article
  18. International journal of molecular sciences · 2024
    Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gabriel L ButterfieldInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Marc J LajoieInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Heather H GustafsonDepartment of Bioengineering, University of Washington, Seattle, Washington 98195, USA.
Drew L SellersDepartment of Bioengineering, University of Washington, Seattle, Washington 98195, USA.
Una NattermannInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Daniel EllisInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Jacob B BaleInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Sharon KeDepartment of Bioengineering, University of Washington, Seattle, Washington 98195, USA.
Garreck H LenzCollege of Arts & Sciences, University of Washington, Seattle, Washington 98195, USA.
Angelica YehdegoSchool of Public Health, University of Washington, Seattle, Washington 98195, USA.
Rashmi RavichandranInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Suzie H PunDepartment of Bioengineering, University of Washington, Seattle, Washington 98195, USA.
Neil P KingInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
David BakerInstitute for Protein Design, University of Washington, Seattle, Washington 98195, USA.

Funding

TRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0M
EXPERIMENTAL PATHOLOGY OF CARDIOVASCULAR DISEASET32HL007312 · NHLBI · UNIVERSITY OF WASHINGTON · PI MAJESKY, MARK W., SCHWARTZ, STEPHEN MARK · 1985 to 2019
$11.8M
POTENTIATING BREAST CANCER THERAPIES BY TARGETING TUMOR-ASSOCIATED MACROPHAGER01CA177272 · NCI · UNIVERSITY OF WASHINGTON · PI PUN, SUZIE H. · 2014 to 2019
$2.0M
Targeting Ligands for autonomic uptake and drug delivery to the brain and spinal cordR21NS099654 · NINDS · UNIVERSITY OF WASHINGTON · PI SELLERS, DREW L · 2017 to 2018
$427k
Howard Hughes Medical InstituteNCI NIH HHS R01 CA177272NHLBI NIH HHS T32 HL007312NIGMS NIH HHS T32 GM007270NIH HHS 5T32HL0071312NINDS NIH HHS R21 NS099654
6 · The paper itself

Abstract

The challenges of evolution in a complex biochemical environment, coupling genotype to phenotype and protecting the genetic material, are solved elegantly in biological systems by the encapsulation of nucleic acids. In the simplest examples, viruses use capsids to surround their genomes. Although these naturally occurring systems have been modified to change their tropism and to display proteins or peptides, billions of years of evolution have favoured efficiency at the expense of modularity, making viral capsids difficult to engineer. Synthetic systems composed of non-viral proteins could provide a 'blank slate' to evolve desired properties for drug delivery and other biomedical applications, while avoiding the safety risks and engineering challenges associated with viruses. Here we create synthetic nucleocapsids, which are computationally designed icosahedral protein assemblies with positively charged inner surfaces that can package their own full-length mRNA genomes. We explore the ability of these nucleocapsids to evolve virus-like properties by generating diversified populations using Escherichia coli as an expression host. Several generations of evolution resulted in markedly improved genome packaging (more than 133-fold), stability in blood (from less than 3.7% to 71% of packaged RNA protected after 6 hours of treatment), and in vivo circulation time (from less than 5 minutes to approximately 4.5 hours). The resulting synthetic nucleocapsids package one full-length RNA genome for every 11 icosahedral assemblies, similar to the best recombinant adeno-associated virus vectors. Our results show that there are simple evolutionary paths through which protein assemblies can acquire virus-like genome packaging and protection. Considerable effort has been directed at 'top-down' modification of viruses to be safe and effective for drug delivery and vaccine applications; the ability to design synthetic nanomaterials computationally and to optimize them through evolution now enables a complementary 'bottom-up' approach with considerable advantages in programmability and control.

Indexed as

BioengineeringDirected Molecular EvolutionGenome, ViralVirus AssemblyAnimalsDrug Delivery SystemsEscherichia coliFemaleGene Products, tatGenetic FitnessGenetic TherapyImmunodeficiency Virus, BovineMiceModels, MolecularNucleocapsidRNA, MessengerGene Products, tatRNA, MessengerRNA, Viral

Identifiers

PMID29236688
PMCPMC5927965

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.